Results 141 to 150 of about 252,929 (281)

Risk for prescription opioid misuse among patients with a history of substance use disorder

, 2012
Benjamin J. Morasco, Dennis C. Turk, Dennis M. Donovan, Steven K. Dobscha   +3 more
openalex   +2 more sources

Socio-demographic and Clinical Profile of Patients with Substance Use Disorder at a Tertiary Care Centre in Vindhya Region: A Hospital-based Study

, 2022
Gyanendra Raghuvanshi, Umesh Pathak, Akshat Varma, Amrendra Kumar Singh   +3 more
openalex   +1 more source

Patatin‐domain‐containing (phospho)lipases under control: Mammalian co‐regulators and pathogenic activation mechanisms

FEBS Open Bio, EarlyView.
Patatin domain‐containing (phospho)lipases are lipid‐hydrolyzing enzymes central to metabolism, membrane remodeling, and signaling. Their activity relies on precise co‐activation mechanisms involving protein–protein interactions and conformational rearrangements.
Noopur Dubey, Lina Riegler‐Berket, Monika Oberer   +2 more
wiley   +1 more source

Medication Availability for Alcohol Use Disorder in Substance Use Disorder Treatment Facilities. [PDF]

JAMA Netw Open
Mizushima Y, Cantor J, McBain RK, Zhang F, Burnett A, Dong E, Kofner A, Breslau J, Stein BD, Yu H.   +9 more
europepmc   +1 more source

Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances

J Havlík, Taeho Greg Rhee, Robert A. Rosenheck   +2 more
openalex   +1 more source

Promiscuous stimulation of HSP70 ATPase activity by parasite‐derived J‐domains

FEBS Open Bio, EarlyView.
The malaria parasite Plasmodium falciparum exports three highly homologous yet functionally divergent J‐domain proteins into human erythrocytes. Here, we show that J‐domains isolated from all three proteins effectively stimulate the ATPase activity of both endogenous host and exported parasite HSP70 chaperones.
Julian Barth, Moritz Koch, Le‐Han Rössner, Johanna Eichhorn, Denys Pogoryelov, Matthias P. Mayer, Jude M. Przyborski   +6 more
wiley   +1 more source

Beyond Addiction: Burden of Polypharmacy and Risk in Frail Patients with Substance Use Disorder. [PDF]

Pharmacy (Basel)
Santiago Gutiérrez LG, Alberto Armas D, Hernández García V, Santana Ayala JR, Sánchez RG, Paz Montelongo S, Gutiérrez ÁJ, Hardisson de la Torre A, Armendáriz CR.   +8 more
europepmc   +1 more source

Letter to the Editor on “Implementation of Network for the Improvement of Addiction Treatment (NIATx) Processes in Substance Use Disorder Treatment Centers”

, 2015
James H. Ford
openalex   +1 more source

Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Mark Baker, Nicola Pavese   +7 more
wiley   +1 more source

Worldwide Research Trends on Substance Use Disorder-Related Inflammatory Imbalances: A Bibliometric Analysis. [PDF]

CNS Neurosci Ther
Cao S, Yang L, Wang R, Liu J.
europepmc   +1 more source